Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG003 + Pucotenlimab in EGFR+ ATC/PDTC
NCT07235566Phase 2
Key facts
- Status
- Recruiting
- Start
- Apr 2025
- Primary completion
- Apr 2029
- Countries
- 1
- Sponsor
- Fudan University
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Drugs
- becotatug vedotin
- Conditions
- anaplastic thyroid cancer (ATC)thyroid cancer
01
Overview
Phase 2, open-label, single-arm trial of becotatug vedotin in anaplastic thyroid cancer (ATC) and thyroid cancer, sponsored by Fudan University. Primary endpoint: Objective Response Rate at 2 years. Started Apr 2025; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Treatment
MRG003 + Pucotenlimab
03
Who it enrols
Patients with pathologically confirmed EGFR-positive (>10% expression) unresectable recurrent or metastatic ATC or PDTC, ECOG 0-1, and adequate organ function. Excludes prior ADC treatment.
04
Endpoints
Primary
Objective Response Rate
Beyond the preview
Go deeper on NCT07235566.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07235566.